NCT02548676

Brief Summary

Glaucoma is one of the leading causes for blindness in industrialized countries. It is characterized by a progressive loss of retinal ganglion cells, morphological changes in the optic nerve head and a characteristic loss of visual field. It has been speculated for a long time that vascular factors may also contribute to the pathogenesis of the disease. This concept has been supported by several epidemiological studies showing that small retinal vessel calibre are associated with the disease. In the recent years tremendous enhancements in the field of optical coherence tomography has been achieved. These developments made it possible to visualize the retinal vasculature in a full depth manner without the application of an intravenous marker. The proposed study tests the hypothesis that patients with glaucoma show altered vascular morphology compared to healthy subjects. This is of importance because it may clarify the degree of vascular involvement in glaucoma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
61

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 4, 2015

Completed
7 days until next milestone

Study Start

First participant enrolled

September 11, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 14, 2015

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
24 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 25, 2016

Completed
Last Updated

April 7, 2022

Status Verified

April 1, 2022

Enrollment Period

1.1 years

First QC Date

September 4, 2015

Last Update Submit

April 6, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Retinal vessel diameter as extracted from the angiograms

    during the four weeks after the first screening day

Secondary Outcomes (3)

  • Systemic hemodynamics (Blood pressure)

    during the four weeks after the first screening day

  • Intraocular pressure

    during the four weeks after the first screening day

  • pulse

    during the four weeks after the first screening day

Study Arms (2)

Glaucoma Patients

Patients with primary open angle glaucoma

Device: Optical angiography based on OCT

Healthy controls

age- and sex matched controls

Device: Optical angiography based on OCT

Interventions

This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.

Glaucoma PatientsHealthy controls

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

30 open angle glaucoma patients 30 healthy age- and sex matched controls

You may qualify if:

  • Diagnosis of manifest open angle glaucoma as defined as pathological optic disc appearance, glaucoma hemifield test outside normal limits and/or untreated IOP ≥ 21 mmHg on at least three measurements in the medical history. Mean deviation in the visual field test \< 10dB

You may not qualify if:

  • Normal ophthalmic findings, IOP ≤ 20mmHg
  • No history of elevated IOP
  • No signs of glaucomatous disc damage

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna

Vienna, Austria

Location

MeSH Terms

Conditions

Glaucoma

Condition Hierarchy (Ancestors)

Ocular HypertensionEye Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc. Prof. PD Dr.

Study Record Dates

First Submitted

September 4, 2015

First Posted

September 14, 2015

Study Start

September 11, 2015

Primary Completion

November 1, 2016

Study Completion

November 25, 2016

Last Updated

April 7, 2022

Record last verified: 2022-04

Locations